Eye Research Foundation, Inc. — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$350,262	12
2023	Research	$3,916	3
2022	Research	$736,700	18
2021	Research	$27,198	10
2019	Research	$560,578	10

Breakdown

Who paid Research payments · program years 2019–2024

Glaukos Corporation $894,134 35 payments
Aerie Pharmaceuticals, Inc. $289,851 3 payments
Dompe US, Inc. $199,577 3 payments
Padagis US LLC $183,750 3 payments
Perrigo Company plc $89,650 5 payments
Oyster Point Pharma, Inc. $18,692 3 payments
Kowa Research Institute, Inc. $3,000 1 payment

Studies the money was for Research payments · program years 2019–2024

Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Travoprost Ophthalmic Topical Cream in Subjects with Open-angle Glaucoma or Ocular Hypertension $331,570 9 payments
A prospective, double-masked, randomized, multicenter, placebo controlled, parallel-group study assessing the safety of two concentrations of netarsudil ophthalmic solution in healthy Japanese/Japanese American volunteers in the United States $289,851 3 payments
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye $199,577 3 payments
Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes $183,750 3 payments
Bioequivalence study between Perrigo's product and Azopt ophthalmic Suspension $68,150 3 payments
Bioequivalence study $21,500 2 payments
A Phase 4, Single-Center, Open-Label Study Evaluating the Safety of the Tyrvaya Nasal Pump $18,692 3 payments
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4, 6 and 8 BID for the Treatment of Signs and Symptoms of Dry Eye Disease $3,761 6 payments
K-161-201 $3,000 1 payment
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6% and 8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease $2,416 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.